Track the companies that matter to you. It's FREE! Click one of these fan favorites to get started: Apple; Google; Ford.



Is More Patent Pain Headed Merck's Way?

Watch stocks you care about

The single, easiest way to keep track of all the stocks that matter...

Your own personalized stock watchlist!

It's a 100% FREE Motley Fool service...

Click Here Now

Merck (NYSE: MRK  ) might be one of big pharma's largest companies, but this health care leader has had a tough go recently. The company's pessimistic earnings report this week showed just how badly patent-related losses have hurt Merck, as its sales plunged by more than 10% year-over-year in the second quarter. Even though investors largely expected a significant blow from former lead blockbuster drug Singulair, which lost patent protection last year and has seen revenue eroded substantially, Merck's decline is troubling for shareholders.

This company's pipeline offers some hope for the future, but it might not be enough to counter Singulair's losses -- and even more patent expirations are headed Merck's way. Let's take a look at the company's drugs that are soon set to lose patent protection and hit sales in a big way.

Zetia, Vytorin, and Merck's at-risk portfolio
The good news for investors is that no one drug on the tail end of its patent life is set to risk as much in sales as Singulair has. Singulair once recorded $5 billion in annual revenue for Merck, and the drug's loss of patent exclusivity has been a hammer blow right up there with Pfizer's Lipitor and other major blockbusters to hit the patent cliff recently.

Unfortunately, a few smaller blockbusters will face patent expirations soon. Chief among Merck's at-risk drugs is the cholesterol-fighting combo of Zetia and Vytorin, which will lose patent protection in 2017. According to Merck's 2012 annual report, a generic version of Zetia is allowed to launch in December 2016.

Zetia and Vytorin put a significant chunk of Merck's revenue at risk. Together, the two drugs fueled more than $4.2 billion in sales last year. That was more than 10% of the company's total pharmaceutical revenue, and few of the company's largest medications are growing at a rate that will combat the two drugs' patent expirations.

Zetia and Vytorin aren't the only two drugs at risk. Allergy and respiratory treatment Nasonex's first patents are set to expire next year, but generic competition likely won't arrive until more patents expire in 2018. The drug delivered more than $1.2 billion in sales next year, although recent revenue growth has been slow: Nasonex's sales actually slumped been 2011 and 2012 and rose only slightly between 2010 and 2011.

A dozen other drugs with smaller sales will lose patent protection between now and 2019. While none of these medications -- from oncology drug Temodar, which pulled in more than $900 million in sales last year and will lose protection next year, to small-time fertility drug Follistim AQ, which pulled in revenue of around $470 million last year -- provide a major part of Merck's sales firepower, they add up to a big bite out of the company's financial foundation.

Offsetting the patent cliff
Merck's pipeline offers up several drugs that should help ease the pain. Osteoperosis drug odanacatib has looked extremely promising in clinical trials. While Merck delayed its regulatory filing for odanacatib until next year, the drug's still poised to take advantage of Eli Lilly's (NYSE: LLY  ) patent loss of its blockbuster bone drug Evista next year. Eli Lilly will shore up Evista's loss with fellow osteoporosis drug Forteo, but the expiration still opens the door for odanacatib's arrival.

Still, Merck's most promising pipeline candidate will face tough competition from Amgen's (NASDAQ: AMGN  ) osteoporosis drug Prolia. Prolia's gotten off to a slow start since its regulatory approval a few years back, but it and fellow Amgen bone drug Xgeva could eclipse the $1 billion annual sales mark in the future. Considering that the rest of Merck's pipeline is average at best, the company will need every dollar of odanacatib to offset losses from Zetia, Vytorin, and other lead drugs set to lose patent protection before 2020.

Ultimately, Merck needs diabetes blockbusters Januvia and Janumet, which reaped more than $5 billion in revenue last year, to perform much better. The two drugs saw only slight growth in the disappointing second quarter. If Merck wants to bounce back from Singulair's losses and beat its oncoming patent expirations, Januvia and Janumet must do better.

Merck's recent woes have caused headaches around health care investor circles, but the company will need to do better if it wants to shine in the long term. The best investors know that it's the big picture that matters for stocks like Merck: While one quarter may be a disappointment, a dark and stormy future for a company is a big red flag for investors. Don't be left guessing on what's ahead: The Motley Fool's special free report "3 Stocks That Will Help You Retire Rich" names specific investment opportunities that could help you build long-term wealth and help you retire well. The Fool also outlines critical wealth-building strategies that every investor should know. Click here to keep reading.

Read/Post Comments (1) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On September 17, 2013, at 4:15 AM, prginww wrote:

    They can kiss my you know what! I REFUSE to pay almost $200.00 for a bottle of Nasonex. I can get the SAME thing from AllDayChemist for $9.99 and that is what I plan on continuing to do. Generic Nasonex exists but it exists in India.

Add your comment.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2569717, ~/Articles/ArticleHandler.aspx, 9/27/2016 10:32:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,172.73 77.90 0.43%
S&P 500 2,152.56 6.46 0.30%
NASD 5,287.61 30.12 0.57%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/27/2016 10:15 AM
MRK $62.19 Up +0.04 +0.06%
Merck and Co. CAPS Rating: ****
AMGN $171.38 Down -2.15 -1.24%
Amgen CAPS Rating: ****
LLY $79.93 Up +0.41 +0.52%
Eli Lilly and Co. CAPS Rating: ***